

RECEIVED
CENTRAL FAX CENTER**MAY 05 2005****CERTIFICATION OF FACSIMILE TRANSMISSION**

I hereby certify that this paper is being facsimile transmitted to the Patent and Trademark Office on the date shown below:


Stephen C. Macevicz
Reg. No. 30,2855 MAY 2005
Date

Pages transmitted (incl cover):



Destination FAX number: (703) 872-9306

Case No. 502.02 (PARAL-7)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor(s): Namsaraev

Serial No: 10/676,933

Filed: 30 September 2003

For: POLYNUCLEOTIDE SYNTHESIS
AND LABELING BY KINETIC
SAMPLING LIGATION

Examiner:

Art Unit: 1637

Confirmation No: 7872

FACSIMILE TRANSMITTAL

Sir:

☒ Transmitted herewith is (are) the following document(s):Fourth Supplemental Information Disclosure Statement
Form 1449


Respectfully submitted,


Stephen C. Macevicz
Reg. No. 30,285Telephone: (650) 892-9848 (cell)
Facsimile: (650) 228-7418

Email: smacevicz@parallelebio.com

CERTIFICATION OF FACSIMILE TRANSMISSION

I hereby certify that this paper is being facsimile transmitted to the Patent and Trademark Office on the date shown below:


Stephen C. Macevicz
Reg. No. 30,285

5 May 2005
Date

Pages transmitted (incl cover): **FOUR (4) PAGES**

Destination FAX number: (703) 872-9306

Case No. 502.02 (PARAL-7)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor(s): Namsaraev

Serial No: 10/676,933

Filed: 30 September 2003

For: POLYNUCLEOTIDE SYNTHESIS
AND LABELING BY KINETIC
SAMPLING LIGATION

Examiner:

Art Unit: 1637

Confirmation No: 7872

FOURTH SUPPLEMENTAL**INFORMATION DISCLOSURE STATEMENT**

Commissioner of Patents and Trademarks
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The references cited on the accompanying PTO-1449 form(s) may be material to the examination of the above-identified application and are, therefore, submitted in compliance with the duty of disclosure defined in 37 CFR 1.56 and 1.97. The Examiner is requested to make these citations of official record in this application. Copies of the cited references are enclosed or have been previously submitted in prior application(s) to the above application.

This Information Disclosure Statement under 37 CFR 1.56 and 1.97 is not to be construed as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one or more of these citations constitutes prior art.


SUBMISSION INFORMATION

- ☒ This Information Disclosure Statement is being submitted within three (3) months of filing or before mailing of a first Office Action, whichever occurs last. (37 CFR 1.97(b))
- ☐ This Information Disclosure Statement is being submitted before the mailing date of either a final Office Action or a Notice of Allowance. (37 CFR 1.97(c)) Applicant elects to pay the fee set forth in 37 CFR 1.17(p) for submission of the Information Disclosure Statement under 37 CFR 1.97(c).
- ☐ This Information Disclosure Statement is being submitted after the mailing date of a final Office Action or Notice of Allowance, whichever occurs first, but before, or simultaneously with, the payment of the issue fee. (37 CFR 1.97(d)) Applicant hereby petitions for the consideration of this Information Disclosure Statement under 37 CFR 1.97(d)(ii). The petition fee under 37 CFR 1.17(i)(1) is authorized or enclosed as indicated below

PAYMENT OF FEES (IF ANY DUE)

- ☐ Check No. _____ in the amount of _____ is enclosed.
- ☐ **FEE AUTHORIZATION.** The Commissioner is hereby authorized to withdraw from Deposit Account
- ☐ Form PTO-2038 for payment by credit card is enclosed.

Respectfully submitted,


Stephen C. Macevitz
Registration No. 30,285

Enclosures: 1449 form(s)

Form PTO-1449 (adapted) REFERENCES CITED BY APPLICANT	Docket No. PARAL-7 US (502.02)	Serial No. 10/676,933
	First Named Inventor Namsaraev	Customer No.
	Filing Date 30 September 2003	Group

U.S. PATENT DOCUMENTS

Examiner's Initial		Country and Document Number	Inventor	Title	Publication Date (dd-mm-yyyy)
	FF3	2003/0096291A1	Faham	Multiplex oligonucleotide addition and target amplification	22 May 2003

EXAMINER	Date considered
*EXAMINER: Initial if reference considered, whether or not citation in conformance with MPEP 609; Draw line through citation if not in conformance and/or not considered. Include copy of this form with next communication to applicant.	